{
    "clinical_study": {
        "@rank": "77206", 
        "acronym": "D-DOSE", 
        "arm_group": [
            {
                "arm_group_label": "5 \u00b5g/day Hy.D Calcifediol", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "10 \u00b5g/day Hy.D Calcifediol", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "15 \u00b5g/day Hy.D Calcifediol", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "20 \u00b5g/day vitamin D3", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the dose of Hy.D Calcifediol 25 SD/S (a metabolite of\n      vitamin D3) which will achieve the range of mean serum 25(OH)D between 75-100nmol/L in\n      physically frail elderly people after 24 weeks of daily supplementation with different doses\n      of Hy.D Calcifediol 25 SD/S compared to vitamin D3."
        }, 
        "brief_title": "Dose Finding Study in Physically Frail Elderly to Measure 25(OH) Vitamin D Levels After Supplementation With Hy.D Calcifediol 25 SD/S and Vitamin D3", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pre-frail Elderly", 
            "Frail Elderly"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  25(OH)D levels between 25 - 50 nmol/L;\n\n          -  Age 65 and older;\n\n          -  Physically frail, based on the criteria designed by Fried et al. [1]. Frailty will be\n             defined as a clinical syndrome in which one or more of the following criteria are\n             present: unintentional weight loss (4.5 kg in past year), selfreported exhaustion\n             (CES-D questionnaire), weakness (grip strength), slow walking speed and low physical\n             activity (Minnesota questionnaire). These criteria are easily assessable and have\n             been commonly used to determine frailty;\n\n          -  Men and women;\n\n          -  Body mass index between 20 and 35 kg/m2 (used for stratification);\n\n          -  Willingness and ability to comply with the protocol.\n\n        Exclusion Criteria:\n\n          -  Medical Illness: malabsorption syndrome: known intestinal malabsorption, celiac\n             diseases, inflammatory bowel disease; diseases that may enhance serum calcium\n             concentration: sarcoidosis, lymphoma, kidney stone in the last 10 years, primary\n             hyperparathyroidism; abnormal indices of calcium metabolism, uncontrolled\n             hypocalcaemia; diagnosed renal insufficiency, diagnosed cancer, diagnosed liver\n             failure.\n\n          -  Hypercalcemia : serum calcium adjusted for albumin of > 2.6 nmol/L.\n\n          -  Medication: bisphosphonate or Parathyroid hormone (PTH) treatment, tuberculostatics,\n             epilepsy medication, interfering with vitamin D metabolism and vitamin D\n             supplementation.\n\n          -  Use of vitamin D supplementation in the last three months (excluding multivitamin\n             supplementation).\n\n          -  Not willing to stop the use of multivitamin supplementation during the study.\n\n          -  (Expected) increase in exposure to sunlight (e.g. travelling to a sunny resort).\n\n          -  Patient heavily consumes alcohol containing products defined as greater than (>) 3\n             drinks (beer, wine, or distilled spirits) of alcoholic beverages per day.\n\n          -  Donating blood in the period of 2 months before, until 1 month after the end of the\n             study.\n\n          -  Planned surgery.\n\n          -  Participation in another clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "65 Years"
        }, 
        "enrollment": {
            "#text": "59", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01868945", 
            "org_study_id": "2012-10-24-HyD"
        }, 
        "intervention": [
            {
                "arm_group_label": "5 \u00b5g/day Hy.D Calcifediol", 
                "description": "5 \u00b5g/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks", 
                "intervention_name": "5 \u00b5g/day Hy.D Calcifediol", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "10 \u00b5g/day Hy.D Calcifediol", 
                "description": "10 \u00b5g/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks", 
                "intervention_name": "10 \u00b5g/day Hy.D Calcifediol", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "15 \u00b5g/day Hy.D Calcifediol", 
                "description": "15 \u00b5g/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks", 
                "intervention_name": "15 \u00b5g/day Hy.D Calcifediol", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "20 \u00b5g/day vitamin D3", 
                "description": "20 \u00b5g/day vitamin D3 taken together with breakfast for a total period of 24 weeks", 
                "intervention_name": "20 \u00b5g/day vitamin D3", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcifediol", 
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Vitamin D3", 
            "Calcifediol 25", 
            "Frail", 
            "Dose-response"
        ], 
        "lastchanged_date": "February 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Wageningen", 
                    "country": "Netherlands", 
                    "zip": "6700"
                }, 
                "name": "Wageningen University"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "4", 
        "official_title": "Dose Finding Study in Physically Frail Elderly to Measure 25(OH) Vitamin D Levels After Supplementation With Hy.D Calcifediol 25 SD/S and Vitamin D3", 
        "overall_official": [
            {
                "affiliation": "Wageningen University", 
                "last_name": "Lisette De Groot, Prof", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Wageningen University", 
                "last_name": "Michael Tieland, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Maastricht University", 
                "last_name": "Luc van Loon, Prof", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Netherlands:  Independent Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Outcome measurement: Mean serum 25(OH)D levels at baseline before supplementation of three doses of Hy.D and 1 dose of vitamin D3.", 
                "measure": "Mean serum 25(OH)D levels in Hy.D and vitamin D3 supplemented groups at baseline", 
                "safety_issue": "No", 
                "time_frame": "Baseline (day 0)"
            }, 
            {
                "description": "Outcome measurement: Mean serum 25(OH)D levels after 4 weeks of supplementation of three doses of Hy.D and 1 dose of vitamin D3.", 
                "measure": "Mean serum 25(OH)D levels in Hy.D and vitamin D3 supplemented groups after 4 weeks", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after initial compound intake"
            }, 
            {
                "description": "Outcome measurement: Mean serum 25(OH)D levels after 8 weeks of supplementation of three doses of Hy.D and 1 dose of vitamin D3.", 
                "measure": "Mean serum 25(OH)D levels in Hy.D and vitamin D3 supplemented groups after 8 weeks", 
                "safety_issue": "No", 
                "time_frame": "8 weeks after initial compound intake"
            }, 
            {
                "description": "Outcome measurement: Mean serum 25(OH)D levels after 12 weeks of supplementation of three doses of Hy.D and 1 dose of vitamin D3.", 
                "measure": "Mean serum 25(OH)D levels in Hy.D and vitamin D3 supplemented groups after 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after initial compound intake"
            }, 
            {
                "description": "Outcome measurement: Mean serum 25(OH)D levels after 16 weeks of supplementation of three doses of Hy.D and 1 dose of vitamin D3.", 
                "measure": "Mean serum 25(OH)D levels in Hy.D and vitamin D3 supplemented groups after 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "16 weeks after initial compound intake"
            }, 
            {
                "description": "Outcome measurement: Mean serum 25(OH)D levels after 20 weeks of supplementation of three doses of Hy.D and 1 dose of vitamin D3.", 
                "measure": "Mean serum 25(OH)D levels in Hy.D and vitamin D3 supplemented groups after 20 weeks", 
                "safety_issue": "No", 
                "time_frame": "20 weeks after initial compound intake"
            }, 
            {
                "description": "Outcome measurement: Mean serum 25(OH)D levels after 24 weeks of supplementation of three doses of Hy.D and 1 dose of vitamin D3.", 
                "measure": "Mean serum 25(OH)D levels in Hy.D and vitamin D3 supplemented groups after 24 weeks", 
                "safety_issue": "No", 
                "time_frame": "24 weeks after initial compound intake"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01868945"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Assessment if 25(OH)D3 serum levels will reach a steady state after 24 weeks supplementation of 3 doses of Hy.D and 1 dose of vitamin D3", 
            "measure": "Descriptive: 25(OH)D3 serum steady state reached?", 
            "safety_issue": "No", 
            "time_frame": "0, 4, 8, 12, 16, 20, 24 weeks after study start"
        }, 
        "source": "DSM Nutritional Products, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "DSM Nutritional Products, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}